Development of the anti-IL-10 mAb MK-1966 in combination with in situ vaccination of a TLR9 agonist SD-101 for cancer immunotherapy. (December 2016) - Phan, U.; Ueda, R.; Mangadu, R.; Sathe, M.; Rimmer, E.; Vives, F.; Ayanoglu, G.; Yu, Y.; Wong, J.; Sadekova, S.; McClanahan, T.; Bhagwat, B.; et al.